Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
betamethasone dipropionate + clotrimazole + gentamicin sulfate
- Development stage
- Unknown
- Lead developer
- RUE Belmedpreparaty
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Compliderm is a topical combination therapy consisting of betamethasone dipropionate, clotrimazole, and gentamicin sulfate. Betamethasone dipropionate is a potent corticosteroid that acts as a glucocorticoid receptor agonist to provide anti-inflammatory, antipruritic, and vasoconstrictive effects. Clotrimazole is an imidazole antifungal that inhibits lanosterol 14-alpha-demethylase, disrupting fungal cell membrane synthesis. Gentamicin sulfate is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Developed by Belmedpreparaty, Compliderm is approved as a generic version of Triderm for the treatment of corticosteroid-responsive dermatoses complicated by secondary bacterial and/or fungal infections.
- Brand names
- Compliderm
- Other names
- betamethasone + clotrimazole + gentamicinbetamethasone dipropionate + clotrimazole + gentamicin sulfatebetamethasone dipropionate, clotrimazole, gentamicin sulfatebetamethasone, clotrimazole, gentamicin
02
Targets
Bacterial RibosomeGR (Glucocorticoid receptor)CYP51A1 (Sterol 14α-demethylase)Cyp (Cyclophilin family)Mitoribosome (Mitochondrial ribosome)
Beyond the preview
Go deeper on betamethasone dipropionate + clotrimazole + gentamicin sulfate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on betamethasone dipropionate + clotrimazole + gentamicin sulfate.